Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Continues Its March To Academia, as Sanofi, UCB Strike Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

In two very different collaborations, Sanofi teams up with Weill Cornell professor to screen for TB drug candidates, while UCB initiates its first project under a strategic research alliance with Harvard.

You may also be interested in...



Takeda Adds Medicinal Chemistry Heft To NYC Research Partnership

Joint research effort by three New York-based academic research organizations seeks to expedite translation of basic biomedical research into innovative therapies. Initial focus is on small molecules, but the plan is to branch out eventually into monoclonal antibodies and molecular imaging agents, as well.

Takeda Adds Medicinal Chemistry Heft To NYC Research Partnership

Joint research effort by three New York-based academic research organizations seeks to expedite translation of basic biomedical research into innovative therapies. Initial focus is on small molecules, but the plan is to branch out eventually into monoclonal antibodies and molecular imaging agents, as well.

Deals Of The Week: AstraZeneca/Ardelyx, Roche/Inception, GlaxoSmithKline/Aeras

Vaxxas thinks its vaccine-enhancement technology platform, Nanopatch, can bring in milestones and royalties just like a biotech drug candidate by offering increased potency and easier administration to makers of vaccines.

Related Content

Topics

UsernamePublicRestriction

Register

PS072447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel